In contrast, a meta-analysis conducted by Sunny Malhotra and colleagues suggested that NLRP3 polymorphisms were not associated with the response to IFN-β treatment in MS (Malhotra et al., 2018). The gene discussed is NLRP3; the disease is myeloid sarcoma.